MedWatch

Snipr Biome to collaborate with US cancer hospital

The Danish company will examine the effect of new CRISPR therapies as a treatment for immune therapy side effects alongside the MD Anderson Cancer Center.

Snipr Biome CEO Christian Grøndahl | Photo: EY / PR

Biotech company Snipr Biome has found a partner to help develop new treatments using CRISPR technology, which targets the human microbiome.

The company has teamed up with renowned US cancer hospital MD Anderson Cancer Center, which is associated with the University of Texas. Snipr Biome will work with a research department at the hospital called PRIME-TR.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs